Find Funding Opportunities

Find Funding Opportunities

Returning 58 results
Filter By:

BRAIN Initiative: Tools to Facilitate High-Throughput Microconnectivity Analysis (R01 Clinical Trial Not Allowed)

RFA
Monday, April 8, 2019
Thursday, October 1, 2020
R01
RFA-MH-20-135

Funding Opportunity Purpose

The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate tools and resources to facilitate the detailed analysis of brain microconnectivity. Novel and augmented techniques are sought that will ultimately be broadly accessible to the neuroscience community for the interrogation of microconnectivity in healthy and diseased brains of model organisms and humans. Development of technologies that will significantly drive down the cost of connectomics would enable routine mapping of the microconnectivity on the same individuals that have been analyzed physiologically, or to compare normal and pathological tissues in substantial numbers of multiple individuals to assess variability. Advancements in both electron microscopy (EM) and super resolution light microscopic approaches are sought. Applications that propose to develop approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged. Proof-of-principle demonstrations and/or reference datasets enabling future development are welcome, as are improved approaches for automated segmentation and analysis strategies of neuronal structures in EM images.no

Institutional Translational Research Training Program (T32)

PAR
Friday, March 22, 2019
Thursday, May 27, 2021
T32
PAR-19-228

Funding Opportunity Purpose

The purpose of the NINDS Institutional Translational Research Training Program is to equip trainees with the knowledge and skills needed to advance basic research toward clinical application. These programs will support, students and/or postdocs conducting basic, disease-relevant research in an environment that includes 1) basic neuroscientists and clinicians who are actively engaged in collaborative research projects, 2) neuroscience researchers with expertise in translational processes who are conducting research designed to move basic discoveries toward clinical application and 3) relationships with industry and government regulatory agencies. Programs will have a cohesive educational approach to translational training in areas relevant to the NINDS mission, and in which students and postdocs learn the processes involved in translational research in the context of their individual projects. Programs supported by this FOA must include activities that ensure a thorough understanding of experimental design, strong statistical and analytical skills, and skills for communicating science with a wide variety of audiences. These programs are intended to be 2 years in duration and support training of one or more of the following groups: advanced predoctoral students, postdoctoral fellows and fellowship-stage clinicians. Upon completion of the program, trainees will be prepared to address basic research problems with an understanding of the requirements for translating discoveries into viable therapies.

Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed)

PAR
Wednesday, March 13, 2019
Thursday, February 17, 2022
U01
PAR-19-220

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials. Through the support of trial readiness studies, NINDS and NCATS expect to enhance the quality and increase the likelihood of success of clinical trials in these rare diseases.

Notice of Special Interest in Research on the Health of Sexual and Gender Minority (SGM) Populations

Notice of Special Interest
Wednesday, March 13, 2019
Sunday, January 1, 2023
NOT-MD-19-001

Funding Opportunity Purpose

Notice Special Interest Research the Health Sexual Gender Minority SGM) Populations Notice Number: NOT-MD-19-001 Key Dates Release Date: March 13, 2019 Related Announcements None Issued National Institute Minority Health Health Disparities NIMHD) National Center Complementary Integrative Health NCCIH) National Cancer Institute NCI) National Human Genome Research Institute NHGRI) National Heart, Lung, Blood Institute NHLBI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Drug Abuse NIDA) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Environmental Health Sciences NIEHS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) Office Behavioral Social Sciences Research OBSSR) Office Disease Prevention ODP) Office Research Women’s Health ORWH) Sexual & Gender Minority Research Office SGMRO) Purpose Notice calls research the health sexual gender minority populations. Sexual gender minority" an umbrella term encompasses lesbian, gay, bisexual, transgender populations well those whose sexual orientation, gender identity expressions, reproductive development varies traditional, societal, cultural, physiological norms. includes individuals disorders differences sex development DSD), sometimes known intersex. Although has an increase SGM-focused health research recent years, remains need further research the health these populations. Notice encourages research describes biological, clinical, behavioral, social processes affect health development SGM populations individuals their families, that leads the development acceptable appropriate health interventions health service delivery methods will enhance health development these populations. Types research are relevant this Notice include, are limited to: Epidemiological research examines patterns risk, morbidity mortality related diseases health conditions have been adequately studied SGM populations. Etiological mechanistic research examining biological, behavioral, social, and/or environmental factors contribute health outcomes health disparities SGM populations. Research leading interventions ameliorate health disparities SGM populations, including formative research identify develop appropriate intervention content well pilot testing interventions establish feasibility, acceptability, preliminary efficacy. Large-scale design, implementation evaluation preventive and/or treatment interventions addressing health issues SGM populations. Possible funding opportunity announcements FOAs) their re-issues which SGM-related research be submitted include are limited Parent FOAs Research R), Career Development K), Fellowship F) awards Parent Announcements Unsolicited Investigator Initiated Applications)": https://grants.nih.gov/grants/guide/parent_announcements.htm. Applicants should carefully note participating Institutes/Centers each FOA. Applications must in mission an Institute/Center listed Components Participating Organizations the FOA. Offices listed this Notice consider co-funding applications assigned an Institute/Center participates the FOA. Investigators strongly encouraged reach to relevant contacts listed below identify FOAs be most appropriate their proposed project application. Applicants should indicate Notice number NOT-MD-19-001) Field 4.b the SF 424 application form refer NOT-MD-19-001 the abstract assist identifying applications submitted this Notice. Areas programmatic interest to NIMHD include are limited to: Observational studies how social determinants, such minority stress, stigma discrimination, lack access culturally competent healthcare, social networks, social support, cause, sustain, ameliorate health disparities. Epidemiological studies the relationship between intersectionality SGM status other health disparity population membership health outcomes. addition SGM populations, NIH-designated health disparity populations include racial/ethnic minorities, socioeconomically disadvantaged populations, underserved rural populations. Intervention studies community healthcare settings reduce health disparities. NIMHD encourages projects use approaches encompass multiple domains e.g., biological, behavioral, socio-cultural, environmental, physical environment, health system) multiple levels e.g., individual, interpersonal, community, societal) understand address health disparities SGM populations the NIMHD Research Framework, https://www.nimhd.nih.gov/about/overview/research-framework.html, examples health determinants interest). Animal studies studies focused SGM populations outside the US not priorities NIMHD under Notice. NCCIH is interested supporting research the of complementary integrative health approaches, including natural products mind body interventions, manage stress, chronic pain, mild anxiety, depression among SGM populations. NCCIH also interested research studying mind body approaches improve adherence treatment e.g., Medication Assisted Treatment MAT) opioid misuse, Antiretroviral therapy ART) HIV) prevention e.g., Pre-exposure prophylaxis PrEP) HIV) regimens promote health outcomes. Natural products include botanicals, pre/probiotics, products marketed dietary supplements. Mind body approaches include various meditation approaches e.g., mindfulness), hypnosis guided imagery, meditative movement approaches e.g., yoga, tai chi, qi-gong), body-based approaches e.g., spinal manipulation, massage, mobilization, acupuncture), combination these approaches e.g., meditation yoga, such in mindfulness-based stress reduction MBSR), complex interventions including music art therapy. NCCIH offers range funding opportunity announcements support clinical trials natural products mind body interventions. Applicants strongly encouraged consult the NCCIH Scientific Research contact prior developing submitting application. Areas programmatic interest to NCI include are limited to) studies that: Identify cancer health care needs across cancer continuum, including prevention, early detection, diagnosis, treatment, survivorship, end life care among SGM populations; Increase understanding the cancer care needs, health outcomes effective interventions improve outcomes SGM individuals; Assess cancer risk inform improved decision-making, risk reduction interventions, screening options early cancer detection SGM populations; Evaluate interventions increase rates screening, follow-up, referral-to-care, improve symptom management cancer prevention control among SGM populations; Increase understanding the barriers cancer health care information treatment may lead SGM individuals/populations avoid delay seeking health care; Examine relative risk cancer cancer risk factors e.g., smoking, obesity, aging, infections such HPV HIV, tobacco use, alcohol consumption, nulliparity) underlying mechanisms risk social, behavioral, biological, clinical) SGM groups comparison their heterosexual counterparts; Investigate cancer patient outcomes, cancer treatment delivery, healthcare utilization SGMs; Improve understanding the differential risks certain types cancers including cervical, breast, ovarian, anal, other malignancies among SGMs; Examine potential cancer risks hormone therapy including off-label use) among transgender and/or intersex individuals; Investigate prevalence rates HPV infection SGM groups the development screening interventions and/or recommendations ameliorate HPV-associated disease; Examine intersection contextual factors e.g., race, geography, socioeconomic status) cancer health outcomes across SGM groups; Investigate lack access and utilization cancer health care services, quality care received, SGM populations impact health outcomes; Assess impact stigma, discrimination, victimization, substance use, other risk factors utilization cancer preventive screening/services; Investigate positive and/or protective factors e.g., family and/or social support) cancer prevention. Areas programmatic interest to NHGRI include are limited to: Development resources, approaches, technologies will accelerate genomic research the structure genomes, biology genomes, the biology disease; Developments will genomics advance science medicine, that incorporate genomics improve effectiveness healthcare; Research several cross-cutting areas, including ethical, legal societal implications genomics research, bioinformatics, research training career development. NHLBI provides global leadership a research, research training, education program promote prevention treatment heart, lung, blood, sleep diseases enhance health all individuals that can live longer more fulfilling lives. NHLBI encourages research designed answer breadth scientific questions related heart, lung, blood, and/or sleep diseases, disorders, phenotypes. NHLBI seeks research applications (R01 applications only) that address questions relevant the NHLBI mission, address gaps the NHLBI’s portfolio clinical epidemiology cohort studies should align the NHLBI’s Strategic Vision. NHLBI’s strategic priorities emphasize continuum research basic molecular biology research implementation science related heart, lung, blood, sleep disorders e.g., Sickle Cell Disease other hemoglobinopathies; cardiovascular diseases; hypertension prevention control; asthma; chronic obstructive pulmonary disease COPD); sleep apnea; other cardiopulmonary diseases conditions), self-management symptoms disease conditions, prevention these diseases disorders various populations. NHLBI also significant interests implementation science research the prevention, control, treatment heart, lung, blood diseases, sleep disorders, particularly research addresses development interventions strategies address translation proven-effective, evidence-based interventions clinical, community, and/or settings; addresses impediments uptake, scale up, sustainability evidence-based research. Please refer the NHLBI website more details the research priorities the NHLBI: https://www.nhlbi.nih.gov/about/documents/strategic-vision. NIA is interested research can improve understanding aging processes and experiences impact health well-being middle-aged older SGM adults well studies focused early life exposures contribute SGM health disparities adulthood. NIA encourages of multi-level analysis individual, dyadic, family, community/institution, population data, consideration multidimensional measures sexual orientation identity, attraction, behavior) diverse gender categories. NIA supports cross-national studies better understand aging experience a global level the effects various policies. Natural experiments”, arising policy change regional differences, provide another powerful approach examining mechanisms affecting health SGM older adults. Applicants encouraged leverage NIA’s investment data infrastructure publicly available datasets. NIA’s Office Research Resources.) Areas programmatic interest to NIA include are limited to: Studies examining interpersonal processes, the situational contexts influence them, lead positive healthy relationships adulthood older age. NIA especially interested research can identify causal mechanisms accounting links between marital status, long-term romantic partnerships, health. Studies examining factors such social identity, intersectionality, positionality, stigma impact interpersonal interactions, well-being, health later life. Causes consequences self-disclosing sexual orientation gender identity mid-late life older age families, intimate partners, employers, health care practitioners, institutions. Studies unique caregiving needs older SGM individuals, especially, individuals Alzheimer’s disease related dementias their families origin chosen). Interventions promote healthy aging reduce health disparities SGM adults. NIA encourages mechanism-focused approach intervention development promoted the NIH Science Behavior Change and the NIH Stage Model. NIA also supports pragmatic trial development Introduction pragmatic clinical trials"). Data infrastructure method development support studies older SGM adults, including development representative population cohorts older SGM adults adequate sample size study issues intersectionality, the addition cohort-sensitive SGM measures existing studies. includes development novel recruitment strategies methods approaches identifying assessing unique issues needs older SGM adults. NIAAA seeks innovative applications the areas of: Epidemiological research examines patterns risk, morbidity mortality related alcohol disorders AUDs) SGM populations, including studies 1) risk protective factors heavy including binge) drinking AUDs; 2) correlates underage drinking related problems among SGM populations; 3) factors influence transitions and of problem drinking patterns across lifespan among SGM populations; 4) consequences, drinking related problems, may attributable the combination racial/ethnic minority status addition SGM status. Etiological mechanistic research—including human laboratory-based research—examining biological, behavioral, social, and/or environmental factors contribute drinking-related outcomes SGM populations. Research leading interventions ameliorate drinking related problems SGM populations, including formative research identify develop appropriate intervention content well pilot testing interventions establish feasibility, acceptability, preliminary efficacy. Design, implementation evaluation preventive and/or treatment interventions address AUDs related problems that appropriate the needs SGM populations. Such projects extend evaluations screening, assessment, brief interventions, referral alcohol treatment; other individual-level preventive approaches, such protective strategies; studies assess drinking prevention approaches enlist families peers online offline); studies focus the effects community/institutional-level alcohol policies preventing drinking related problems among SGM populations; studies look alcohol treatment efficacy among SGM populations. Areas programmatic interest to NIAID include are limited to: Research all areas HIV infection, including developing testing preventive HIV vaccines, other prevention strategies, new treatments HIV infection AIDS-associated opportunistic infections Basic applied research better understand, treat, ultimately prevent infectious, immunologic, allergic diseases. Training career development e.g. T, F, K) applications rural urban institutions may underserved SGM populations. mission of NIAMS is support research the causes, treatment, prevention arthritis musculoskeletal skin diseases; training basic clinical scientists carry this research; the dissemination information research progress these diseases. NIAMS also conducts supports basic research the normal structure function bones, joints, muscles, skin. Basic research involves wide variety scientific disciplines, including immunology, genetics, molecular biology, structural biology, biochemistry, physiology, virology, pharmacology. Clinical research areas include rheumatology, orthopaedics, dermatology, metabolic bone diseases, heritable disorders bone cartilage, inherited inflammatory muscle diseases, sports rehabilitation medicine. NIAMS also seeks studies include sufficient numbers SGM individuals enable robust sub-group analyses. Clinical trials designed answer specific questions the safety, tolerability, efficacy, effectiveness, clinical management, and/or implementation pharmacologic, behavioral, biologic, surgical, device invasive non-invasive) interventions only supported NIAMS submitted a NIAMS clinical trials-specific FOA. current list active NIAMS clinical trials FOAs available at https://www.niams.nih.gov/grants-funding/conducting-clinical-research/grants. information regarding NIAMS supported scientific areas/programs contacts, please see:https://www.niams.nih.gov/grants-funding/supported-scientific-areas. The NICHD supports biological, behavioral, clinical research related conception pregnancy, normal abnormal development childhood, reproductive health, population dynamics across lifespan, rehabilitation medicine https://www.nichd.nih.gov/grantsfunding/opportunities-mechanisms/areas-research/Pages/default.aspx). Research projects considered funding NICHD must fall within scientific missions the twelve Scientific Branches the NICHD Division Extramural Research DER) the National Center Medical Rehabilitation Research NCMRR). Information those scientific missions program staff contacts be found the web pages the DER scientific branches at: http://www.nichd.nih.gov/about/org/der/branches/Pages/index.aspx and NCMRR at: http://www.nichd.nih.gov/about/org/ncmrr/Pages/overview.aspx. Potential applicants strongly encouraged read webpages any updates response recent scientific advances emerging public health topics. NICHD encourages applications address extramural program priorities will consider well research projects align one more those priorities making award decisions. detailed list NICHD high priority research areas be found at https://www.nichd.nih.gov/grants-funding/opportunities-mechanisms/areasresearch/Pages/priorities.aspx Areas programmatic interest to NIDA include are limited to: Innovative drug abuse epidemiology, prevention, health services research among SGM populations; Translational research applies findings epidemiology, cognitive science, neuroscience, other sciences develop test novel prevention interventions among SGM populations; Treatment development research testing substance disorders, including behavioral treatments, among SGM populations; Vulnerability addiction biological etiology among SGM populations; Behavioral cognitive mechanisms consequences substance polysubstance among SGM populations. Areas programmatic interest to NIDCR include are limited to: Research craniofacial skeletal tissue homeostasis, injury, repair the presence hormone therapy Epidemiologic research the prevalence unmet dental, oral, and/or craniofacial needs SGM individuals, e.g., oral cancers, oral complications HIV/AIDS, orofacial trauma Research identifying explanatory mechanisms oral health disparities SGM individuals populations Research reduce oral health disparities SGM individuals populations, targeting individual, family, community, provider, health system, and/or policy levers change NIDDK supports medical research research training dissemination science-based information diabetes other endocrine metabolic diseases; digestive diseases, nutritional disorders, obesity; kidney, urologic, hematologic diseases, improve people’s health quality life. Areas programmatic interest to NIEHS include are limited to: Studies better understand impact environmental exposures, such endocrine disrupting chemicals, gonadal development other hormonal systems affect sexual development Development resources, approaches, technologies will promote research environmental conditions effect health sexual gender minority populations Areas programmatic interest to NIMH include: Identification mutable mechanistic causes disparities mental health-related clinical including suicide thoughts behaviors) functional outcomes including Severe Mental Illness) which interventions targeting health equity be developed tested. could include interventions the individual, family, provider, clinic system-level, based the empirical evidence the contributing factor(s). Descriptive studies the prevalence characteristics mental disorders SGM individuals considered low priority. more details NIMH support intervention studies, please see: https://www.nimh.nih.gov/funding/opportunities-announcements/clinical-trials-foas/index.shtml. Studies how non-mental health specialty settings e.g., SGM social support groups, human resources employee assistance programs, educational settings, etc.) contribute and support screening, referral, diagnosis treatment prevention mental illness suicide behavior SGM populations. development testing stigma reduction interventions and/or interventions address social cultural barriers not only change knowledge/attitudes/beliefs also lead behavior change consumers providers) structural change the clinic system level) improves access, engagement, retention, treatment adherence, quality care mental health outcomes including suicide risk) SGM across life course. Studies proposing adapt/augment interventions SGM racial ethnic minority groups should provide empirical basis the need intervention tailoring how is expected achieve equity mental health-related outcomes among those groups. Studies better understand disparities HIV rates outcomes among SGM living HIV how mitigate as well a better understanding the factors impeding scale of efficacious HIV prevention interventions SGM the development approaches address barriers. NIMH also seeks studies that: Include sufficient numbers SGM individuals enable robust sub-group analyses. Conduct secondary data analyses identify strategies improving quality mental health care SGM individuals. Areas programmatic interest to NINDS include are limited to: Research health disparities SGM populations relevant neurological disorders fall within scientific mission the NINDS https://www.ninds.nih.gov/About-NINDS/Who-We-Are/Mission). Research the effects exogenous hormone among transgender and/or intersex individuals neurological function neurological disorders. Research risk factors neurological disorders SGM populations. Inquiries Please direct inquiries to: Jennifer Alvidrez, PhD National Institute Minority Health Health Disparities NIMHD) Telephone: 301-594-9567 Email: jennifer.alvidrez@nih.gov Della B. White, PhD National Center Complementary & Integrative Health NCCIH) Telephone: 301-827-6358 Email: Della.White@nih.gov Elizabeth Perruccio, PhD National Cancer Institute NCI) Telephone: 240-276-6178 Email: liz.perruccio@nih.gov Christine Gatlin, Ph.D. National Human Genome Research Institute NHGRI) Telephone: 301-480-2280 Email: gatlincl@mail.nih.gov Brad Newsome, PhD National Heart, Lung, Blood Institute NHLBI) Telephone: 301-827-8170 Email: brad.newsome@nih.gov Melissa S. Gerald, PhD National Institute Aging NIA) Telephone: 301-496-3136 Email: melissa.gerald@nih.gov Robert C. Freeman, PhD National Institute Alcohol Abuse Alcoholism NIAAA) Telephone: 301-443-8820 Email: rfreeman@mail.nih.gov Philip Renzullo, PhD, MPH National Institute Allergy Infectious Diseases NIAID) Telephone: 240-627-3041 Email: prenzullo@niaid.nih.gov Heiyoung Park, PhD National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Telephone: 301-594-3507 Email: Heiyoung.Park@nih.gov Regina Bures, PhD Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) Telephone: 301-496-9485 Email: regina.bures@nih.gov Jeffrey Schulden, MD National Institute Drug Abuse NIDA) Telephone: 301-402-1526 Email: schuldenj@nida.nih.gov Dena Fischer, DDS, MSD, MS National Institute Dental Craniofacial Research NIDCR) Telephone: 301-594-4876 Email: dena.fischer@nih.gov Tamara Bavendam, MD, MS National Institute Diabetes Digestive Kidney Diseases NIDDK) Telephone: 301-594-4733 Email: bavendamtg@mail.nih.gov Thaddeus Schug, PhD National Institute Environmental Health Sciences NIEHS) Telephone: 984-287-3319 Email: schugt2@niehs.nih.gov Tamara Lewis-Johnson, MBA, MPH National Institute Mental Health NIMH) Telephone: 301-594-7963 Email: tamara.lewisjohnson@nih.gov Richard T. Benson, MD, PhD National Institute Neurological Disorders Stroke NINDS) Phone: 301-496-9135 E-mail: Richard.benson@nih.gov Kate Winseck, MSW Office Disease Prevention ODP) Telephone: 301-827-5583 Email: winseckk@mail.nih.gov Victoria Cargill, MD, MSCE, AAHIVS Office Research Women’s Health ORWH) Telephone: 301-435-0971 Email: cargillv@od.nih.gov Karen L. Parker, PhD, MSW Sexual & Gender Minority Research Office SGMRO) Telephone: 301-451-2055 Email: Klparker@mail.nih.gov

Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial Not Allowed)

PA
Wednesday, October 17, 2018
Wednesday, February 3, 2021
333
PA-19-029

Funding Opportunity Purpose

This funding opportunity announcement (FOA) seeks to develop and nurture a national innovation ecosystem that builds upon biomedical research to develop technologies, products, and services that benefit society. Toward meeting this objective, the I-Corps program is being offered. The I-Corps at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. Under this FOA, participating NIH and CDC Institutes and Centers will continue providing administrative supplement awards to currently-funded SBIR and STTR Phase I grantees. The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH and Centers for Disease Control and Prevention (CDC) SBIR and STTR funding. It is anticipated that outcomes for the I-Corps teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact NIH or CDC Scientific/Research staff for more information about the program before applying.

Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)

PAR
Friday, October 5, 2018
Friday, April 16, 2021
U01
PAR-18-951

Funding Opportunity Purpose

The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs).

Pre-application: Opportunities for Collaborative Research at the NIH Clinical Center (X02 Clinical Trial Optional)

PAR
Friday, October 5, 2018
Saturday, December 12, 2020
X02
PAR-18-950

Funding Opportunity Purpose

The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs).

Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43)(Clinical Trial Optional)

PAR
Monday, August 13, 2018
Saturday, November 14, 2020
PAR-18-901

Funding Opportunity Purpose

This funding opportunity announcement (FOA) encourages applications for the Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) D43 program for institutional research training programs in low-and middle-income countries (LMICs, as defined by the World Bank classification system). Applications may be for collaborations between institutions in the U.S and an eligible LMIC or may involve just LMIC institutions if there is a previous track record of externally funded research and/or research training programs by the lead LMIC institution. The proposed institutional research training program is expected to sustainably strengthen the NCD research capacity of the LMIC institutions, and to train in-country experts to develop and conduct research on NCDs across the lifespan, with the long-range goal of developing and implementing evidence-based interventions relevant to their countries. The main focus of research training covered in the application must be relevant to the interests of at least one of the participating NIH ICs as stated by each in this FOA. Other NCD topics may be included as secondary and complementary focus areas.

Administrative Supplements to Promote Diversity in Small Businesses-SBIR/STTR (Admin Supp Clinical Trial Not Allowed)

PA
Wednesday, June 20, 2018
Sunday, September 5, 2021
333
PA-18-837

Funding Opportunity Purpose

The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) hereby notify Small Business Concerns (SBCs) holding Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants that funds are available for administrative supplements to improve the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from groups that have been shown to be nationally underrepresented in health-related research or in the SBIR program. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)

PAR
Thursday, April 19, 2018
Translational Research
Saturday, May 8, 2021
R61/R33
PAR-18-763

Funding Opportunity Purpose

This funding opportunity announcement (FOA) encourages the development and validation of: 1) animal models and human tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological disorder and/or 2) clinically feasible pharmacodynamic markers for therapeutics designed to treat neurological disease. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models, ex vivo systems, and pharmacodynamic markers that will be utilized to facilitate the development of neurotherapeutics. Ideally, models, model systems and pharmacodynamic markers proposed in applications for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) focused on enabling the exploratory and early stages of drug discovery.

Pages